Eli Lilly Reports Results of Lartruvo (olaratumab) in ANNOUNCE P-III Study for Advanced or Metastatic Soft Tissue Sarcoma (STS)

Shots:

• The P-III ANNOUNCE study involves assessing of Lartruvo + doxorubicin following lartruvo monothx vs doxorubicin + PBO following PBO monothx in patients with advanced or metastatic STS
• The study didn’t meet 1EP as OS showing no difference in survival rate with no safety signals observed; AEs (all grades; grade 3-4) fatigue (69%,9% vs 3% 69%); musculoskeletal pain (64%, 8% vs 25%, 2%); decreased appetite (31%, 2% vs 20%, 0%); lymphopenia (77%, 44% vs 73%, 37%); hypokalemia (21%, 8% vs 15%, 3%)
• Lartruvo (olaratumab) is a platelet-derived growth factor receptor alpha (PDGFR-α) mAb used for blocking PDGFR-α and prevents receptor activation, indicated for soft tissue sarcoma (STS) in combination with doxorubicin

Click here to read full press release/ article | Ref: Eli Lilly | Image:GMP news